Application of Fluconazole-Loaded pH-Sensitive Lipid Nanoparticles for Enhanced Antifungal Therapy

Sarigama Rajesh1, Sheeana Gangadoo1, Han Nguyen1

  • 1School of Science, RMIT University, 124 La Trobe St., Melbourne, VIC 3000, Australia.

Insights

Researchers developed pH-sensitive lipid nanoparticles (LNP) to deliver fluconazole (Fluc) effectively against drug-resistant Cryptococcus neoformans. This novel approach targets acidic infection sites, enhancing antifungal treatment and combating resistance.

Area of Science:

  • Biomedical Engineering
  • Mycology
  • Drug Delivery

Background:

  • Cryptococcus neoformans causes life-threatening cryptococcal meningitis.
  • Increasing antifungal resistance, particularly to fluconazole (Fluc), leads to high mortality rates.
  • Current treatments struggle with drug resistance and targeted delivery.

Purpose of the Study:

  • To develop a novel pH-sensitive lipid nanoparticle (LNP) system for improved fluconazole (Fluc) delivery.
  • To enhance the targetability and efficacy of Fluc against resistant Cryptococcus neoformans strains.
  • To exploit the acidic microenvironment of fungal infections for targeted drug release.

Main Methods:

  • Formulation of pH-sensitive LNPs using monoolein (MO) and 2-morpholinoethyl oleate (O2ME).
  • Characterization of LNP nanostructure (hexosomes/cubosomes) and charge at different pH levels.
  • Evaluation of LNP-Fluc efficacy using MIC50/MIC90 assays and microscopy (confocal and scanning electron).

Main Results:

  • LNPs exhibited pH-dependent structural and charge transitions (hexosomes at neutral pH, cubosomes at acidic pH).
  • Acidic pH-triggered LNPs showed enhanced interaction with fungal cell walls.
  • LNP-Fluc demonstrated significantly lower MIC50 and MIC90 values compared to free Fluc.
  • Microscopy confirmed severe fungal cell damage and cytoplasmic leakage upon LNP-Fluc treatment at acidic pH.

Conclusions:

  • pH-sensitive LNPs represent a promising strategy for targeted antifungal drug delivery.
  • This approach effectively overcomes fluconazole resistance in Cryptococcus neoformans.
  • The study advances targeted antifungal therapy for combating antimicrobial resistance.